^
    Back
    Association details:
    Biomarker:CD19 positive + CD20 positive
    Cancer:Burkitt Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    FT596 (CD19 inhibitor, IL-15R stimulant, CD16A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2020
    Title:

    2216 / 21 - Combinational strategy targeting B cell malignancy using iPSC engineered CAR-NK (FT596) and CAR-T cell (FT819) platforms with therapeutic antibody to achieve an effective deep and durable response

    Published date:
    05/14/2020
    Excerpt:
    FT596 also shows enhanced clearance of CD19+CD20+ Burkitts lymphoma cell line RAJI when used in combination with rituximab (p=0.0002 vs rituximab alone) . Collectively, these studies suggest a compounded anti-tumor effect can be achieved utilizing the inherent properties of engineered CAR-iNK cells together with therapeutic antibody combined with engineered CAR-iT cells which will be highlighted in this presentation.
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

    Published date:
    11/01/2019
    Excerpt:
    ...CD19+CD20+ Burkitts lymphoma cell line RAJI, and enhanced clearance of RAJI tumor cells in combination with rituximab (p=0.0002). Furthermore, utilizing an allogenic human CD34 engrafted NSG mouse model, FT596 demonstrated improved survival and safety over primary CAR19 T cells, either as a monotherapy or as a combination therapy with rituximab versus RAJI tumor cells.
    DOI:
    10.1182/blood-2019-129319